

Title (en)
BIOCOMPATIBLE POLYMER CONJUGATES.

Title (de)
BIOVERTRAGLICHES POLYMERKONJUGAT.

Title (fr)
CONJUGUES POLYMERES BIOCOMPATIBLES.

Publication
EP 0648239 A4 19950927 (EN)

Application
EP 93916926 A 19930701

Priority

- US 90751892 A 19920702
- US 92254192 A 19920730
- US 98419792 A 19921202
- US 98493392 A 19921202
- US 98568092 A 19921202
- US 2503293 A 19930302
- US 9306292 W 19930701

Abstract (en)
[origin: WO9401483A1] Pharmaceutically acceptable, non-immunogenic conjugates are formed by covalently binding a biologically inactive, natural polymer or derivative thereof to pharmaceutically pure, synthetic hydrophilic polymers via specific types of chemical bonds. The biocompatible conjugates can be used for soft tissue augmentation and for coating or forming various articles. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as liquid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The conjugates generally contain large amounts of water when formed and can be dehydrated to form a solid object which can subsequently be ground into particles and suspended in a non-aqueous fluid for injection into a mammal to provide the soft tissue augmentation.

IPC 1-7
C08G 63/48; **C08G 63/91**; **C08H 1/00**; **A61K 38/17**

IPC 8 full level
A61K 38/00 (2006.01); **A61K 38/21** (2006.01); **A61K 38/22** (2006.01); **A61K 47/48** (2006.01); **A61L 24/10** (2006.01); **A61L 26/00** (2006.01); **A61L 27/00** (2006.01); **A61L 27/18** (2006.01); **A61L 27/20** (2006.01); **A61L 27/24** (2006.01); **A61L 27/26** (2006.01); **A61L 27/34** (2006.01); **A61L 27/44** (2006.01); **A61L 27/54** (2006.01); **A61L 29/04** (2006.01); **A61L 29/06** (2006.01); **A61L 29/16** (2006.01); **A61L 31/04** (2006.01); **A61L 31/10** (2006.01); **A61L 31/12** (2006.01); **C07K 14/495** (2006.01); **C07K 14/78** (2006.01); **C08B 37/00** (2006.01); **C08B 37/08** (2006.01); **C08G 65/32** (2006.01); **C08G 81/00** (2006.01); **C08H 1/00** (2006.01); **C08H 1/06** (2006.01); **C09J 189/06** (2006.01); **A61F 2/00** (2006.01); **A61F 2/06** (2006.01); **A61F 2/07** (2013.01)

CPC (source: EP)
A61K 47/61 (2017.07); **A61L 24/102** (2013.01); **A61L 26/0033** (2013.01); **A61L 27/18** (2013.01); **A61L 27/20** (2013.01); **A61L 27/24** (2013.01); **A61L 27/26** (2013.01); **A61L 27/34** (2013.01); **A61L 27/44** (2013.01); **A61L 27/54** (2013.01); **A61L 29/043** (2013.01); **A61L 29/045** (2013.01); **A61L 29/06** (2013.01); **A61L 29/16** (2013.01); **A61L 31/041** (2013.01); **A61L 31/044** (2013.01); **A61L 31/10** (2013.01); **A61L 31/125** (2013.01); **C07K 14/495** (2013.01); **C07K 14/78** (2013.01); **C08B 37/0069** (2013.01); **C08B 37/0072** (2013.01); **C08H 1/06** (2013.01); **C09J 189/06** (2013.01); **A61F 2/07** (2013.01); **A61F 2310/00365** (2013.01); **A61K 38/00** (2013.01); **A61L 2300/236** (2013.01); **A61L 2300/414** (2013.01); **A61L 2300/426** (2013.01); **A61L 2430/16** (2013.01); **C08L 2666/02** (2013.01)

Citation (search report)

- [X] WO 9005755 A1 19900531 - COLLAGEN CORP [US]
- [X] US 3091542 A 19630528 - ANDERSON ARTHUR W
- [A] US 4487865 A 19841211 - BALAZS ENDRE A [US], et al
- [A] WO 9204048 A2 19920319 - BIOMEMBRANE INST [US]
- [X] DATABASE WPI Week 8907, Derwent World Patents Index; AN 51979
- See references of WO 9401483A1

Cited by
EP0713707A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9401483 A1 19940120; AU 4662093 A 19940131; AU 677789 B2 19970508; EP 0648239 A1 19950419; EP 0648239 A4 19950927; JP H08502082 A 19960305

DOCDB simple family (application)
US 9306292 W 19930701; AU 4662093 A 19930701; EP 93916926 A 19930701; JP 50342794 A 19930701